Abbott Laboratories
ABT
Market Cap$192.43B
Close$
Earnings Call Q4 2023
January 24, 2024 - AI Summary
Abbott reported strong fourth quarter results, with organic sales growth of 2.1% and double-digit growth in underlying base business sales.
The company provided a positive outlook for 2024, forecasting organic sales growth of 8% to 10% (excluding COVID testing) and adjusted earnings per share of $4.50 to $4.70.
Abbott's diversified portfolio and strategic investments during the pandemic have positioned the company for sustainable growth beyond the pandemic.
Exclusive for Stockcircle Pro members
Sign up
$111.43
5.2% upside
Current Fair Value
5.2% upsideUndervalued by 5.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $192.43 Billion |
|---|---|
| Enterprise Value | $199.83 Billion |
| Dividend Yield | $2.0545 (1.85%) |
| Earnings per Share | $3.27 |
| Beta | 0.43 |
| Outstanding Shares | 1,735,184,289 |
| Avg 30 Day Volume | 7,069,853 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 33.62 |
|---|---|
| PEG | 61.91 |
| Price to Sales | 4.6 |
| Price to Book Ratio | 4.81 |
| Enterprise Value to Revenue | 4.98 |
| Enterprise Value to EBIT | 30.85 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.38 |
Revenue Sources
No data
ESG Score
No data
About Abbott Laboratories
CEO: Robert Ford